This fact sheet is for men who would like to know more about bisphosphonates to relieve pain in prostate cancer that has spread to the bones.
Last updated June 2015 Due to be reviewed June 2017
Bader P, Echtle D, Fonteyne V, Livadas K, De Meerleer G, Paez Borda A, et al. Guidelines on pain management. European Association of Urology; 2010.
British Uro-oncology Group (BUG), British Association of Urological Surgeons (BAUS). Multi-disciplinary Team (MDT) Guidance for Managing Prostate Cancer. 2013.
British Uro-oncology Group (BUG), British Association of Urological Surgeons (BAUS): Section of Oncology, British Prostate Group (BPG). MDT (Multi-disciplinary Team) Guidance for Managing Prostate Cancer 2nd Edition (November 2009). 2009.
Deng X, He G, Liu J, Luo F, Peng X, Tang S, et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treatment Reviews. 2014 Jul;40(6):730–8.
Drudge-Coates L, Turner B. Bone micro-environment in prostate cancer: impact, treatment and implications for nursing practice. International Journal of Urological Nursing. 2012 Jul;6(2):83–90.
Drudge-Coates L, Turner B. Treatment-related osteonecrosis of the jaw: presentation and management. cancer nursing practice. 2012;11(5):28–36.
electronic Medicines Compendium. Zometa 4mg/5ml Concentrate for Solution for Infusion [Internet]. [cited 2015 Feb 24]. Available from: http://www.medicines.org.uk/EMC/medicine/14062/SPC/Zometa+4mg+5ml+Concentrate+for+Solution+for+Infusion/
electronic Medicines Compendium. Zometa 4mg/100ml Solution for Infusion [Internet]. [cited 2015 Feb 24]. Available from: http://www.medicines.org.uk/EMC/medicine/25058/SPC/Zometa+4mg+100ml+Solution+for+Infusion/
Electronic Medicines Compendium. Zometa 4mg/100ml Solution for Infusion - Patient Information Leaflet (PIL) [Internet]. [cited 2015 Feb 24]. Available from: http://www.medicines.org.uk/emc/medicine/25059/PIL/Zometa+4mg+100ml+Solution+for+Infusion
Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff KC, Canallatos P, et al. Osteonecrosis of the jaw – Prevention and treatment strategies for oral health professionals. Oral Oncology. 2013 Sep;49(9):878–86.
Husson O, Mols F, van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Annals of Oncology. 2011 Apr 1;22(4):761–72.
Healthcare Improvement Scotland. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE (Multiple) Technology Appraisal Guidance No 265 [Internet]. [cited 2015 May 13]. Available from: http://www.healthcareimprovementscotland.org/programmes/nice_guidance_and_scotland/mta_resources/appraisal_265.aspx?iru=FV15K62K54
Jacobs C, Ng T, Ong M, Clemons M. Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits. Current Opinion in Supportive and Palliative Care. 2014 Dec;8(4):420–8.
Lee S-H, Chan R-C, Chang S-S, Tan Y-L, Chang K-H, Lee MC, et al. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies. Supportive Care in Cancer. 2014 Feb;22(2):553–60.
MHRA. Drug Safety Update. 2009.
Morgans AK, Smith MR. Bone-Targeted Agents. Urologic Clinics of North America. 2012 Nov;39(4):533–46.
Mundy GR, Roodman GD, Smith MR. New Opportunities for the Management of Cancer-Related Bone Complications. 2009 [cited 2013 Nov 4]; Available from: http://www.curatio-cme.com/newsletters/CAHO_New_Opp_May2009.pdf
National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
NICE. CG58 Prostate cancer: NICE guidance [Internet]. [cited 2013 Jan 9]. Available from: http://publications.nice.org.uk/prostate-cancer-cg58
Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, Öhrling K, et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Supportive Care in Cancer [Internet]. 2014 Dec 23 [cited 2015 Feb 18]; Available from: http://link.springer.com/10.1007/s00520-014-2525-4
Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nature Reviews Rheumatology. 2012 Feb;8:90–6.
Scottish Medicines Consortium. Zoledronic acid (Zometa®) [Internet]. [cited 2015 May 13]. Available from: https://www.scottishmedicines.org.uk/SMC_Advice/Advice/Zoledronic_acid__Zometa__-_Independent_Review/Zoledronic_acid__Zometa___IPR
Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews Clinical Oncology [Internet]. 2011 May 10 [cited 2013 Dec 11]; Available from: http://www.nature.com/doifinder/10.1038/nrclinonc.2011.67
Yuen KK, Shelley M, Sze WM, Wilt TJ, Mason M. Bisphosphonates for advanced prostate cancer (Review). Cochrane Database of Systematic Reviews. 2006;(4).
This fact sheet is for men who have been diagnosed with advanced (metastatic) prostate cancer - cancer that has spread from the prostate to other parts of the body. It explains what advanced prostate cancer is, what your test results mean, and the treatments available.
This booklet is for men who are having hormone therapy for prostate cancer, their partners and families. It describes the different types of hormone therapy, how they work and what the treatment involves. It includes information on the possible side effects men may experience and suggests ways to help manage these.